CClinicalTrials.gg
CompletedNCT01558284Neu-P11Updated Feb 5, 2014

The Effect of Neu-P11 on Symptoms in Patients With D-IBS

An observational study in Diarrhea- Irritable Bowel Syndrome, sponsored by Ludwig-Maximilians - University of Munich. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-02-05.

Sponsored by Ludwig-Maximilians - University of Munich · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 79 Years
Sex
All
01

Study summary

Placebo controlled double-blind study with 40 patients who have an diarrhea-predominant IBS, 20 get Neu-P11, 20 get a placebo. Neu-P11 is a, Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist.

Read the detailed description

This study aims to test a possible beneficial effect of NEU-P11 in patients with IBS.

The effect on symptoms will be rated by symptom scores. The primary endpoint will be the symptomatic benefit reported by the patient answering the simple question: Did your symptoms improve compared to prior to the clinical trial.

Additional secondary endpoints will capture sleep quality, changes in stool texture and individual symptom scores employing standardized symptom scores.

The study design is a 4 week, randomised, placebo-controlled, double blind study where 40 patients receive either placebo (20) or NEU-P11 (20). In the mid of the four week time of the Study the dose can be doubled of the patient does not recognize any relief of the D-IBS.

02

Conditions studied

  • Diarrhea- Irritable Bowel Syndrome

Keywords

  • Irritable bowel syndrome
  • Neu-P11
  • Melatonin
  • D-IBS
03

In context

Irritable Bowel Syndrome

1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.

This study's enrollment of 40 is below the median of 150 across 178 observational studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

Ludwig-Maximilians - University of Munich is the lead sponsor of 218 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diarrhea-praedominant Irritated Bowel Syndroms

Inclusion criteria

  1. Subjects age 18-80 years old
  2. Male or female

    Women of childbearing potential must have a negative pregnancy test at the screening visit, on Day 1 of each treatment period, and use a reliable method of contraception during the entire study duration and for at least 3 months after study drug intake. Reliable methods of contraception are:

    • oral contraception
    • Double barrier type devices (e.g., male or female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.
    • Intra-uterine devices in combination with a spermicide. Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception. Women not of childbearing potential are defined as postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.
  3. Subject has IBS confirmed by the Rome III diagnostic criteria

Exclusion criteria

Exclusion Criteria:

  1. Subject has current evidence of duodenal ulcer, gastric ulcer, diverticulitis, or infectious gastroenteritis.
  2. Subject has a history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, celiac disease), GI malignancy, GI obstruction, gastroparesis, carcinoid syndrome, pancreatitis, amyloidosis or ileus
  3. Subject is a candidate for GI surgery or has a history of GI surgery except appendectomy and cholecystectomy.
  4. Subject has psychiatric disorders which are not controlled (based on the investigator medical judgment); subject with psychosis are excluded regardless of current therapy.
  5. Subject has current or recent history (within 12 months of signing on informed consent) of drug or alcohol abuse.
  6. Subject is pregnant or lactating
  7. Subject has history of human immunodeficiency virus (HIV) or hepatitis (B or C)
  8. Subject has any condition or circumstance that could cause noncompliance with treatments or visits
  9. Subject has active malignancy within the last 5 years.
  10. Subject taking antipsychotic drugs, antispasmodics, antidiarrheals (e.g. loperamide, lubiprostone and bismuth subsalicylate), narcotics, prokinetic drugs, drugs indicated for IBS (e.g Alosetron), or warfarin.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (actual)

Interventions

  • DrugNeu-P11

    Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist

    Also known as: there are no other names

  • DrugPlacebo

    Placebo

    Also known as: there are no other names

06

What researchers measure

Primary outcomes

  1. The relief of symptoms of the D-IBS by the study medication.

    Only one question at the end of each visit and of each telephone call

    Time frame: after each week for the time of study

07

Study locations

1 site
  • Klinikum Grosshadern Medizinische Klinik 2
    Munich, Bavaria 81377, Germany
08

References and documents

Publications

  • Storr M. [Therapy of gastroesophageal reflux disease (GERD)]. Med Monatsschr Pharm. 2011 Dec;34(12):446-54; quiz 455-6. German. PubMed 22233024 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01558284
Lead sponsor
Ludwig-Maximilians - University of Munich
Responsible party
Martin Storr (Prof Dr., Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
Mar 20, 2012
Start date
Feb 2012
Primary completion
Jan 2014
Completion
Feb 2014
Last update
Feb 5, 2014

Study contacts

Martin Storr, Prof Dr.
principal investigator · Medizinische Klinik 2 LMU Muenchen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion